

N-Acetylgalactosamine-4-Sulfatase

[View the current N-Acetylgalactosamine-4-Sulfatase InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/N-Acetylgalactosamine-4-Sulfatase.html)

(<http://www.bioportfolio.com/indepth/N-Acetylgalactosamine-4-Sulfatase.html>)

Recent Publications on N-Acetylgalactosamine-4-Sulfatase:



- [Maroteaux-Lamy syndrome: functional characterization of pathogenic mutations and polymorphisms in the arylsulfatase B gene.](#)
Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome) is an autosomal... 16th September, 2008
Departament de Genetica, Facultat de Biologia, Universitat de Barcelona,- *Mol Genet Metab.* 2008 Jul;94(3):305-12. Epub 2008 Apr 10. ([DOI Direct Link](#))
- [Genetic analysis of mucopolysaccharidosis type VI in Taiwanese patients.](#)
BACKGROUND: Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy... 6th September, 2008
Department of Medical Research, China Medical University Hospital, 2 Yuh- *Clin Chim Acta.* 2008 Aug;394(1-2):89-93. Epub 2008 Apr 27. ([DOI Direct Link](#))
- [Mucopolysaccharidosis type VI \(Maroteaux-Lamy syndrome\): assessment of joint mobility and grip and pinch strength.](#)
OBJECTIVE: To describe the profile of joint mobility and grip and pinch... 5th September, 2008
Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS),- *J Pediatr (Rio J).* 2008 Mar-Apr;84(2):130-5. Epub 2008 Mar 18. ([DOI Direct Link](#))
- [Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.](#)
The objective of this study was to evaluate the long-term clinical... 15th August, 2008
Children's Hospital & Research Center Oakland, 747 52nd Street, Oakland,- *Mol Genet Metab.* 2008 Aug;94(4):469-75. Epub 2008 May 23. ([DOI Direct Link](#))
- [In vivo specific reduction of arylsulfatase B enzymatic activity in children with cystic fibrosis.](#)
OBJECTIVE: To describe the profile of joint mobility and grip and pinch... 22nd July, 2008
- *Mol Genet Metab.* 2008 May;94(1):139. Epub 2008 Mar 4. ([DOI Direct Link](#))
- [Distinct effects of N-acetylgalactosamine-4-sulfatase and galactose-6-sulfatase expression on chondroitin sulfates.](#)
The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B... 29th May, 2008
Department of Medicine, University of Illinois, Chicago, IL 60612, USA.- *J Biol Chem.* 2008 Apr 11;283(15):9523-30. Epub 2008 Feb 18. ([DOI Direct Link](#))
- [Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle.](#)
Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of... 14th May, 2008
Telethon Institute of Genetics and Medicine, Naples, Italy.- *Mol Ther.* 2008 Jan;16(1):30-7. Epub 2007

Oct 23. ([DOI Direct Link](#))

- [Structural and clinical implications of amino acid substitutions in N-acetylgalactosamine-4-sulfatase: insight into mucopolysaccharidosis type VI.](#)
To elucidate the basis of mucopolysaccharidosis type VI (MPS VI) from the... 22nd April, 2008
Graduate School of Agricultural and Life Sciences, The University of- *Mol Genet Metab.* 2008 Apr;93(4):419-25. Epub 2008 Jan 8. ([DOI Direct Link](#))
- [Reversed papilledema in an MPS VI patient with galsulfase \(Naglazyme\(\(R\)\)\) therapy.](#)
MPS VI (mucopolysaccharidosis VI, known as Maroteaux-Lamy syndrome) is a... 18th April, 2008
Children's Hospital Oakland, 5275 Claremont Ave, Oakland, CA, 94618, USA,- *Int Ophthalmol.* 2008 Apr 17. ([DOI Direct Link](#))
- [Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B \(galsulfase \[Naglazyme\]\).](#)
Our patient with mucopolysaccharidosis type VI received enzyme replacement... 21st March, 2008
Division of Genetics, Birth Defects, and Metabolism, Children's Memorial- *Pediatrics.* 2008 Mar;121(3):e714-7. Epub 2008 Feb 4. ([DOI Direct Link](#))
- [Molecular markers for the follow-up of enzyme-replacement therapy in mucopolysaccharidosis type VI disease.](#)
MPS VI (mucopolysaccharidosis type VI) is a lysosomal storage disease in... 15th March, 2008
Department of Biochemistry and Medical Biotechnologies, University of- *Biotechnol Appl Biochem.* 2008 Mar;49(Pt 3):219-23. ([DOI Direct Link](#))
- [Identification of the molecular defects in Spanish and Argentinian mucopolysaccharidosis VI \(Maroteaux-Lamy syndrome\) patients, including 9 novel mutations.](#)
Maroteaux-Lamy syndrome, or mucopolysaccharidosis VI (MPS VI), is an... 6th December, 2007
Departament de Genetica, Facultat de Biologia, Universitat de Barcelona,- *Mol Genet Metab.* 2007 Sep-Oct;92(1-2):122-30. Epub 2007 Jul 20. ([DOI Direct Link](#))
- [Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI.](#)
Degenerative joint disease (DJD) is one aspect of mucopolysaccharidosis VI... 25th October, 2007
Lysosomal Diseases Research Unit, Department of Genetic Medicine,- *Mol Genet Metab.* 2007 Aug;91(4):352-61. Epub 2007 Jun 1. ([DOI Direct Link](#))
- [Human sulfatases: a structural perspective to catalysis.](#)
The sulfatase family of enzymes catalyzes hydrolysis of sulfate ester... 14th September, 2007
Hauptman-Woodward Medical Research Institute and Roswell Park Cancer- *Cell Mol Life Sci.* 2007 Aug;64(15):2013-22. ([DOI Direct Link](#))
- [\[Overview of enzyme replacement therapy in mucopolysaccharidosis\]](#)
Mucopolysaccharidosis are rare, multisystemic and progressive diseases... 29th June, 2007
Centre de Reference des Maladies Hereditaires du Metabolisme, Hopital- *Presse Med.* 2007 Mar;36 Spec No 1:1S96-9.

N-Acetylgalactosamine-4-Sulfatase Clinical Trials:



- [Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI](#)
Mucopolysaccharidosis VI



N-Acetylgalactosamine-4-Sulfatase Patents:

- 7429474- [2-O sulfatase compositions and methods of analyzing therewith](#)
- 6534302- [22438, 23553, 25278, and 26212 novel human sulfatases](#)
- 6582692- [Recombinant adeno-associated virus virions for the treatment of lysosomal disorders](#)
- 6677137- [Avian and reptile derived polynucleotide encoding a polypeptide having heparanase activity](#)
- 6767727- [22438, 23553, 25278, and 26212 novel human sulfatases](#)
- 6780627- [22438, 23553, 25278, and 26212 novel human sulfatases](#)
- 6866844- [Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme](#)
- 6972124- [Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme](#)
- 7029895- [27411, a novel human PGP synthase](#)
- 7033790- [Proteins and nucleic acids encoding same](#)
- 7147837- [Bioactivated diagnostic imaging contrast agents](#)
- 7247445- [2-O sulfatase compositions and methods of hydrolyzing therewith](#)
- 7270815- [2-O sulfatase compositions and related methods](#)
- 7396824- [2-O sulfatase nucleic acid compositions](#)
- 6153188- [Glycosylation variants of iduronate 2-sulfatase](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

